Amgen announced that first-in-human data from a Phase I study investigating the experimental drug AMG 510 in adults with locally-advanced or metastatic KRASG12C mutant solid tumours will be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. The small-molecule therapy, which irreversibly inhibits KRASG12C, is being studied as both monotherapy and in combination with an anti-PD-L1 monoclonal antibody in a variety of solid tumour settings.
In an abstract released ahead of the meeting, tumour response results were detailed for nine patients, while 13 subjects have not reached their first assessment. Data showed that one subject with non-small-cell lung cancer (NSCLC) had a partial response, six participants had stable disease, four with colorectal cancer and two with NSCLC, and two had progressive disease. Researchers noted that a second partial response was reported in a patient with NSCLC after the data cut-off date.
According to the abstract, 17 of the 22 patients had received had at least three prior lines of treatment. The investigators said that the maximum tolerated dose has not been determined, and enrolment into the dose exploration is ongoing with 20 subjects continuing to receive AMG 510.